Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical leader pioneering targeted radiotherapies for advanced cancers, with a focus on acute myeloid leukemia (AML) and stem cell transplant conditioning. This page provides investors and healthcare professionals with timely updates on the company’s clinical trials, regulatory milestones, and scientific advancements.
Access verified news about Actinium’s antibody radiation conjugate (ARC) pipeline, including Iomab-B and Actimab-A, alongside strategic partnerships in oncology. Our curated repository ensures efficient tracking of developments in targeted radiotherapy, clinical research collaborations, and progress toward addressing unmet needs in hematologic malignancies.
Explore updates across key categories: clinical trial results, FDA communications, intellectual property expansions, and scientific presentations. Bookmark this page to stay informed on Actinium’s innovative approaches to minimizing treatment toxicity while improving outcomes for high-risk cancer patients.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced that multiple abstracts showcasing its Iomab-B and Actimab-A clinical programs are set for presentation at the 63rd American Society of Hematology Annual Meeting in Atlanta, GA, from December 11-14, 2021. Notably, the pivotal Phase 3 SIERRA trial for Iomab-B has completed patient enrollment, with interim data to be presented at ASH. The company aims to demonstrate the efficacy of its targeted therapies in improving outcomes for patients with unmet medical needs, particularly in AML treatments.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced that two abstracts on targeted radiotherapies combined with CD47 antibody immunotherapy will be presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) from November 12-14, 2021. The titles focus on enhancing anti-tumor effects in solid tumors and acute myeloid leukemia. CEO Sandesh Seth expressed excitement about the R&D advancements and the company's efforts in the immunotherapy field. Full posters will be available on Actinium's website on November 9, 2021.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. The company's presentation is scheduled for September 29 at 3:20 p.m. ET. Attendees can access the webcast via Actinium's investor relations website. Actinium focuses on developing targeted radiotherapies, particularly Antibody Radiation-Conjugates, aimed at improving treatment outcomes for cancer patients with high unmet needs. The company's lead candidate is I-131 apamistamab (Iomab-B), being studied in pivotal trials.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced several key senior leadership appointments aimed at advancing its growth strategy. Arun Swaminathan, Ph.D., has been appointed as Chief Business and Commercial Officer, while Paul Diamond, Ph.D., joins as Vice President, Patent and Legal Counsel. Avinash Desai, M.D., has been promoted to Chief Medical Officer. These leaders together bring over 50 years of experience in biopharmaceuticals, enhancing Actinium's focus on its pipeline, particularly the recently completed Phase 3 SIERRA trial for Iomab-B.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced its participation in four upcoming investor conferences, highlighting its pivotal Phase 3 trial for Iomab-B and upcoming milestones from its targeted radiotherapy pipeline. The conferences are scheduled from September 27 to October 13, 2021. CEO Sandesh Seth emphasized the strong momentum as the company approaches significant data updates in the fourth quarter. Actinium specializes in targeted radiotherapies aimed at treating patients with unmet needs, focusing on improving outcomes through innovative therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has completed enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B, aimed at treating patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial, involving 150 patients across 24 centers in the U.S. and Canada, assesses the efficacy of Iomab-B in providing Bone Marrow Transplant (BMT) access. Actinium plans to present data updates in Q4 2021 and topline results in mid-2022 to support a Biologics License Application (BLA) for Iomab-B.
Actinium Pharmaceuticals (NYSE: ATNM) announced its inclusion in the Russell Microcap® Index effective June 28, 2021. This membership, determined by market-cap rankings, will last for one year and grants Actinium access to associated growth and value style indexes. The Russell indexes are critical benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. As a clinical-stage biopharmaceutical company, Actinium focuses on developing innovative therapies, notably its lead candidate I-131 apamistamab, which is under study for conditioning before bone marrow transplants.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the enhancement of its intellectual property portfolio for its lead candidate, Iomab-B, with patents granted in the EU and Japan. These patents, covering the composition and administration methods of Iomab-B, are expected to be valid through 2036 and 2037. Actinium aims to leverage its patents for aggressive development in targeted conditioning, particularly for bone marrow transplants and cell therapies. The company holds multiple patents globally and enjoys orphan drug designation for Iomab-B, potentially providing market exclusivity.
Actinium Pharmaceuticals (NYSE: ATNM) presented promising data from its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 SNMMI Annual Meeting. Iomab-B, a radiotherapy targeting CD45, aims to enable potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial showed a remarkable 100% BMT and engraftment rate in the Iomab-B group, while only 18% in the control arm. With 75% patient enrollment completed, the results highlight Iomab-B's potential to transform treatment outcomes in this challenging patient population.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
